BioCentury | Jan 23, 2021
Politics, Policy & Law

CMS rule should improve biosimilar Part D access, but isn’t silver bullet

...a flood.” That flood will include biosimilars of the current highest selling drug: anti-TNF mAb Humira...
...see biosimilar competition starting in 2023. Six adalimumab biosimilars are approved. AbbVie reported 2019 full-year Humira...
BioCentury | Dec 15, 2020
Regulation

Test of strength: Boehringer says FDA policy tilts playing field against biosimilars

...concentration of reference, biosimilar products By Steve Usdin, Washington Editor Among the many properties of Humira...
...that was first approved in 2002.Having received FDA approval for Cyltezo, a biosimilar version of Humira...
...of licensing agreements that provide a path through the patent thicket AbbVie has assembled around Humira...
BioCentury | Oct 6, 2020
Politics, Policy & Law

Treating Trump & BMS’s $13B MyoKardia buy: a BioCentury podcast

...arthritis drug and also used for other autoimmune diseases. The leader in their therapeutic class Humira...
BioCentury | Oct 3, 2020
Politics, Policy & Law

Congressional Democrats rehearse drug pricing attacks

...AbbVie Inc. (NYSE:ABBV) of a competing drug, Humira...
BioCentury | Oct 3, 2020
Product Development

How virtual drug launches could change the biopharma industry

...Enbrel etanercept, marketed by Amgen Inc. (NASDAQ:AMGN),  and Humira...
BioCentury | Oct 1, 2020
Politics, Policy & Law

House committee targets Mallinckrodt, Amgen and Novartis over price increases

...price increases taken by AbbVie Inc. (NYSE:ABBV) of Humira...
...committee, however, indicate that Amgen executives viewed Humira’s...
BioCentury | Sep 2, 2020
Regulation

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

...issue a subpoena to AbbVie Inc. (NYSE:ABBV) for documents regarding pricing strategies for autoimmune drug Humira...
BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

...back (see “Aducanumab Filing Delayed” ). Mylan, Fujifilm Kyowa Kirin gain U.S. approval for biosimilar Humira...
...In accordance with a patent license agreement with AbbVie Inc. (NYSE:ABBV), Mylan will launch the Humira...
BioCentury | Jun 11, 2020
Deals

In course correction, AbbVie steers toward innovation with Genmab deal

...offset future generic competition for its top seller, Humira adalimumab (see “AbbVie Looks to Fill Humira...
BioCentury | May 1, 2020
Finance

Skyrizi continues to outperform as AbbVie looks to fill Humira gap

...likely have a blockbuster drug to help offset future generic competition for its top seller Humira...
...looks like.” AbbVie is relying on Skyrizi and other launches to offset eroding sales of Humira...
Items per page:
1 - 10 of 858